trial · primary record
Frexalimab
Type 1 Diabetes Mellitus
| Phase | Phase 2 |
|---|---|
| Status | ACTIVE |
| Sponsor | Unknown |
| Enrolment | 197 |
| Primary completion | 2030-10-29 |
| Primary endpoint | Change in mean 2h mixed meal tolerance test (MMTT) stimulated C-peptide concentration, calculated from AUC from baseline to W52 for Part B (12-21 y.o.) |
| Registry ID | NCT06111586 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-11-02T15:47:43.254Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT06111586
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.